Study Objective: To assess the frequency of intrauterine pathology among women with abnormal uterine bleeding (AUB) while taking hormone replacement therapy (HRT), and correlate pathology with clinical features.
Design: Retrospective review (Canadian Task Force classification II-2).
Setting: University teaching hospital-based outpatient clinic.
Patients: Ninety-nine women.
Intervention: Observational evaluation.
Measurements And Main Results: Intrauterine pathology was found in 16 (18.6%) of 99 women with AUB. The frequency was 4 times higher in those with AUB after achieving amenorrhea with a continuous combined regimen of HRT than in those with AUB with only 6 months of HRT. It was also higher in patients taking a continuous combined regimen in whom AUB lasted for more than 6 months.
Conclusion: Hysteroscopic examination with endometrial sampling is recommended if AUB continues after the first 6 months of HRT or if it occurs after a period of amenorrhea.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1074-3804(05)60308-8 | DOI Listing |
Sci Rep
January 2025
Department of Gynecology, Chongqing Ninth People's Hospital, 69, Jialing Village, Beibei District, Chongqing, 400700, China.
This study investigated the risk factors for endometrial hyperplasia (EH) and endometrial carcinoma (EC) in premenopausal women. The goal was to establish a nomogram model to predict the risk of EH/EC and quantitative standards in clinical practice, which improved the clinical prognosis of EH/EC patients. Data were collected from premenopausal women with suspected EH/EC who underwent hysteroscopic endometrial biopsy.
View Article and Find Full Text PDFAndes Pediatr
October 2024
Facultad de Medicina Occidente, Universidad de Chile, Santiago, Chile.
Polycystic Ovary Syndrome (PCOS) is the most common endocrine-metabolic disorder in female adolescents, and it is associated with metabolic, cardiovascular, and reproductive complications. Recent findings also suggest an association with psychiatric pathology, both affected patients and their offspring. In this update, we synthesized the recent literature on mental health in women and adolescents with PCOS through a systematic search in PubMed, Epistemonikos, and Scielo for articles published in the last 5 years.
View Article and Find Full Text PDFJ Minim Invasive Gynecol
January 2025
Department of Reproductive Endocrinology, University Hospital Zurich, Frauenklinikstr. 10, 8910, Zurich, Switzerland.
Study Objective: The association between endometriosis and congenital uterine anomalies (CUAs) has been discussed for decades, but existing evidence about this association is scarce. The aim of our study is to evaluate the prevalence of CUAs in women with endometriosis and to identify specific characteristics in women with both CUAs and endometriosis in a large cohort of patients.
Design: This is a retrospective single-center observational study conducted between January 2006 and June 2021.
Obstet Gynecol Sci
January 2025
Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong.
This systematic review and meta-analysis aimed to summarize the pregnancy outcomes of women di-agnosed with genital tuberculosis (GTB) who spontaneously conceived or underwent intrauterine in-semination (IUI) or in vitro fertilization (IVF) after being treated with antitubercular therapy (ATT). Pub-lications from the PubMed, Medline, Embase, Ovid, Scopus, Web of Science, and Google Scholar data-bases were searched from December 20, 2021, to March 5, 2022. The outcomes are presented as pooled averages with 95% confidence intervals.
View Article and Find Full Text PDFJ Int AIDS Soc
January 2025
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Introduction: Long-acting injectable cabotegravir (CAB-LA) for pre-exposure prophylaxis significantly reduced HIV acquisition in HPTN 084. We report on the safety and CAB-LA pharmacokinetics in pregnant women during the blinded period of HPTN 084.
Methods: Participants were randomized 1:1 to either active cabotegravir (CAB) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) placebo or active TDF/FTC plus CAB placebo.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!